ROCHE : UBS lowers price target
' Roche's Q4 EBIT miss was followed by guidance for FY2024 below UBS and market expectations '.
' The momentum remains challenging until clear progress is made ' says UBS.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Go to the original article.
Contact us to request a correction